Cassava Sciences (NASDAQ:SAVA) is up ~3.3% in the premarket after Jones Trading initiated its coverage with a buy rating with the price target of ~$110.0 per share indicating ~110.9% upside to the previous close.
The analyst Soumit Roy expects Cassava to benefit from the bullish sentiment in the Alzheimer’s disease space.
SAVA ,Jones Trading initiated its coverage with a buy rating wi
本帖于 2021-03-17 06:25:44 时间, 由普通用户 雨夫子 编辑